Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,499,362

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Arpita Dutt headshot

Is This the Right Time to Invest in Biotech Stocks?

The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?

    Inovio (INO): What's in the Cards this Earnings Season?

    Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.

      BioDelivery (BDSI): What's in Store this Earnings Season?

      BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.

        The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E

        The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E

          Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View

          The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.

            Mark Vickery headshot

            Top Research Reports for February 28, 2017

            Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Visa (V) and Biogen (BIIB).

              Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

              Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

                Arpita Dutt headshot

                Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

                Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

                  The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean

                  The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean

                    Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

                    Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                        Biogen (BIIB) Beats on Q4 Earnings; Misses Sales

                        BIIB???s fourth quarter 2016 earnings were better-than expected. The company posted earnings of $5.04 per share while our consensus called for EPS of $4.97.

                          Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA

                          Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.

                            Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY

                            How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?

                              Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

                              Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

                                Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug

                                Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.

                                  The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway

                                  The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway

                                    Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit

                                    Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.

                                      Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?

                                      Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.

                                        Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017

                                        We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.

                                          The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal

                                          The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal

                                            Biogen (BIIB) Presents Positive Phase III Data on Spinraza

                                            Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).

                                              Arpita Dutt headshot

                                              Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

                                              Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

                                                Biogen Licenses Amunix's XTEN Technology for Factor IX Drug

                                                Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.

                                                  Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data

                                                  Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.